Pfizer/BioNTech Finalize 300 Million Dose Vaccine Supply Deal for Europe
Pfizer and German drugmaker BioNTech have finalized a deal with the European Commission to supply 300 million doses of their messenger RNA-based COVID-19 vaccine, BNT162b2, to the European Union.
Pending regulatory approval by the European Medicines Agency, distribution would start by year’s end from manufacturing facilities in Germany and Belgium.
Earlier this week, the companies announced that BNT162b2 was more than 90 percent effective based on data from 94 participants in a phase 3 trial. Pfizer remains on track to submit a request for an Emergency Use Authorization to the FDA in the third week of November.